This was the first study to evaluate the safety, efficacy, pharmacokinetics, and pharmacodynamics of a highly potent, non-bile acid FXR agonist, tropifexor, in patients with PBC who had an inadequate response to UDCA.16 The gene discussed is NR1H4; the disease is primary biliary cholangitis.